Share This Page
Drugs in ATC Class H01CC
✉ Email this page to a colleague
Drugs in ATC Class: H01CC - Anti-gonadotropin-releasing hormones
| Tradename | Generic Name |
|---|---|
| FYREMADEL | ganirelix acetate |
| GANIRELIX ACETATE | ganirelix acetate |
| CETRORELIX ACETATE | cetrorelix acetate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class H01CC (Anti-gonadotropin-releasing hormones): what protects key drugs, when exclusivity ends, and where generic or biosimilar entry risks sit
ATC H01CC covers anti-gonadotropin-releasing hormone (GnRH) therapies used mainly in hormone-sensitive conditions. Market dynamics are dominated by GnRH antagonist durability (oral and depot formats), patent thickets around depot/microsphere and in situ forming systems, and regulatory bottlenecks created by FDA reference product dependency (for small-molecule) and PBLA/biologic pathway dependencies (for peptide formulations where applicable). Patent strategy typically concentrates on: (1) drug substance/formulation variants, (2) depot or prolonged-release manufacturing and particle or polymer systems, and (3) method-of-use claims tied to specific indications and dosing regimens.
This article maps the competitive and IP landscape for H01CC by focusing on the leading marketed anti-GnRH agents by formulation type, and outlines the typical exclusivity and litigation vectors that control H01CC generic entry.
Which drugs fall under ATC H01CC, and how does this shape the patent estate?
ATC Class H01CC is generally associated with anti-gonadotropin-releasing hormones, with the marketed portfolio led by elagolix and relugolix (oral GnRH antagonists in clinical use) and degarelix and cetorelix (injectable GnRH antagonists historically and in certain geographies). In practice, patent estates in H01CC split along two technical vectors: oral small-molecule formulations and injectable prolonged-release depots.
What are the dominant H01CC therapeutic use areas?
- Prostate cancer (often advanced hormone-sensitive or castration-resistant contexts, depending on label and geography)
- Endometriosis and uterine fibroids (oral antagonists in particular)
Why do formulation formats drive exclusivity and litigation risk?
- Injectable depot products require hard-to-design around polymer systems, particle size distributions, sterilization and manufacturing controls, and stability/bridging studies.
- Oral antagonists create more “manufacturing-only” differentiation, but formulation (salt forms, polymorphs, particle engineering, coatings) still supports patent layering.
What patents protect elagolix and relugolix (oral anti-GnRH antagonists), and how are claims typically structured?
Elagolix and relugolix are the highest relevance oral products for H01CC from a generic-entry perspective because the market has clear oral dosing platforms and ongoing lifecycle management.
Patent claim categories seen in oral anti-GnRH programs
- Drug substance composition claims
- Specific chemical entities, stereochemistry, and salt forms
- Pharmaceutical composition claims
- Tablets/capsules, specific excipient systems, disintegrants, binders, coatings
- Polymorph/crystal form claims
- Stabilized forms, process-dependent forms
- Manufacturing/process claims
- Routes to produce specific intermediates or controlled crystal attributes
- Method-of-use (indication and regimen)
- Dose ranges, titration schedules, combination regimens
How do these patents control generic entry?
- Paragraph IV leverage: claim-coverage is often strongest for crystalline forms and composition details rather than the core chemical entity after early substance expiry.
- Design-around: switching to alternate salts or polymorphs is often possible but triggers the need for bioequivalence and may collide with polymorph/process claims.
What depot and prolonged-release patents protect degarelix and other injectable anti-GnRH therapies?
Degarelix represents the injectable antagonists segment where depot technology and manufacturing are core to IP coverage.
Depot-related IP that tends to be hardest to design around
- Polymer or solvent system specifications
- Particle size distribution targets for microspheres or in situ forming systems
- Stabilization chemistry and storage conditions
- Manufacturing steps that achieve controlled release kinetics
- Sterility assurance and aseptic filling processes
Litigation and generic risk profile for depots
Depot generics typically face higher barriers:
- longer CMC development and more extensive characterization
- higher chance of infringing formulation or manufacturing process claims
- higher odds that patents survive on composition and method-of-use grounds
When does H01CC exclusivity end for leading anti-GnRH drugs?
Exclusivity outcomes in H01CC are a function of two time regimes:
- Patent expiry (composition, method-of-use, and formulation)
- Regulatory exclusivity (data exclusivity and patent term restoration, where applicable)
How exclusivity typically stacks for oral and injectable H01CC products
- Oral small molecules often see earlier substance expiry, followed by later-life patent layers (salts/polymorphs, formulation compositions, and dosing regimens).
- Injectable antagonists often extend exclusivity longer through depot-specific patents that cover the release mechanism and manufacturing.
Practical timeline dynamics
- Generic launch is usually timed to:
- the end of primary composition claim coverage, plus
- any remaining formulation/form-fill patents,
- and the expiration of active ingredient related patents that block ANDA approval.
What is the Orange Book status of anti-GnRH (H01CC) products, and what does that mean for ANDA strategy?
Orange Book status determines what patents are listed for FDA-reviewed drug products and what hurdles ANDA applicants face. For H01CC, the practical outcome is:
- where Orange Book lists multiple patents per NDA, ANDA applicants often must resolve more than one infringement claim set.
- where only method-of-use patents remain late in the lifecycle, generic developers may file to carve out or attempt noninfringement by choosing different dosing patterns or label strategies.
ANDA risk drivers in H01CC
- Number of Orange Book-listed patents
- Whether remaining patents are composition/formulation or only method-of-use
- Strength of prosecution history estoppel and claim scope breadth
Which patent estate is strongest in H01CC: oral antagonists or depot injectable antagonists?
Comparative patent “strength” signals used in H01CC deals and litigation
- Claim density: number of separate independent claims still active near expiry
- Formulation depth: whether salts/polymorphs/process are covered
- Regimen specificity: whether method-of-use claims are tied to narrow dosing schedules that generics must replicate
- Infringement plausibility: proximity of generic candidate product attributes to claimed parameters (particle size, excipient set, release profile)
Market implication
- Oral antagonists generally have more pathways for label and manufacturing design-around, but formulation and polymorph patents can still delay entry.
- Injectable depot antagonists usually have fewer generic entrants because CMC and release profile claims constrain “equivalent” substitutes.
What generic entry risks exist for H01CC drugs under Paragraph IV ANDAs?
How Paragraph IV challenges tend to play out in H01CC
- If early substance patents have expired, Paragraph IV often targets later patents:
- polymorph/crystal claims
- composition and excipient claims
- depot formulation and manufacturing methods
- method-of-use claims tied to indication and dosing regimen
- Courts often focus on product attribute matching, including crystallinity, particle size, dissolution profile, and process steps.
Typical settlement patterns that shape market dynamics
Where an ANDA is challenged, settlements often:
- delay launch through agreed “carve-out” dates
- include license payments tied to the timing of generic entry
- sometimes impose label restrictions (especially where method-of-use patents remain)
How does H01CC patent landscape affect revenue exposure for brand manufacturers?
Revenue exposure is driven by:
- remaining exclusivity windows by product format
- intensity of the patent wall (composition/formulation vs method-of-use only)
- whether multiple competitors are in the “at-risk” pipeline
- whether depot vs oral increases time-to-launch
Revenue sensitivity map (conceptual)
- Oral H01CC: higher probability of incremental erosion from multiple generic candidates if formulation patents are contestable or narrow
- Depot H01CC: lower probability of multiple entrants due to CMC complexity and stronger depot-linked IP
What patent litigation affects anti-GnRH drugs, and how do settlements change the launch calendar?
In H01CC, the litigation effect commonly shows up in:
- delayed launch after a Paragraph IV filing
- “date-certain” settlement barriers that move launch beyond what would be expected from a simple patent expiry calendar
- label carve-outs that reduce branded exposure in specific sub-indications rather than full label conversion
Litigation touchpoints that matter for investors and planners
- District court determinations on claim construction for formulation and regimen claims
- Federal Circuit outcomes on claim scope or invalidity standards
- Consent judgments or stipulations that fix later launch dates
How do biosimilar pathways apply to H01CC anti-GnRH therapies?
Most H01CC anti-GnRH agents are small molecules, so biosimilar pathways are typically not the main route for follow-on competition. The relevant question for the H01CC market is usually:
- whether any anti-GnRH products are treated as biologics under U.S. regulatory classifications (rare for this class)
- if any depot formulations incorporate protein/peptide components that would require a biologic pathway (less typical in core H01CC)
Where biosimilars do apply, the controlling exclusivity is:
- reference product biological exclusivity and any interchangeability-related constraints
- a different litigation pattern than ANDA Paragraph IV, typically PBLA-related
How does the H01CC competitive landscape differ by route of administration?
Oral (elagolix/relugolix-type dynamics)
- faster reformulation cycles
- more freedom for generic applicants to pursue alternate polymorphs and salts
- higher reliance on bioequivalence and formulation patents
Injectable depot (degarelix-type dynamics)
- high CMC friction
- release-profile matching is the gating item
- formulation/manufacturing process patents frequently remain as the last barrier
Key Takeaways
- H01CC patent estates typically concentrate on formulation and dosing regimen layers that extend beyond initial drug substance expiry, with injectable depots having the strongest design-around barriers.
- Orange Book listings and the mix of composition versus method-of-use patents largely determine ANDA entry difficulty and settlement leverage.
- Market erosion is usually fastest for oral anti-GnRH where formulation patents are narrow or contested; depot antagonists face fewer generic entrants due to CMC and depot-release IP constraints.
- Paragraph IV challenges in H01CC frequently target later-life formulation and regimen patents rather than the core chemical entities.
FAQs
Which H01CC patents most often survive to block ANDA approval?
Formulation composition, polymorph/crystal form, and method-of-use dosing regimen patents often remain active when primary substance claims expire.
How do formulation patents change generic launch timing in ATC H01CC?
They can force additional development and can trigger infringement assessments based on dissolution profile, crystallinity, and excipient systems.
Do depot anti-GnRH products have higher generic entry barriers than oral anti-GnRH?
Yes, depot prolonged-release systems usually face stronger CMC-related constraints and more difficult claim design-arounds tied to release kinetics and manufacturing.
What settlement terms most affect H01CC brand revenue risk?
Date-certain launch delays, label carve-outs, and cross-licenses that extend effective exclusivity beyond statutory expiry.
Are biosimilars a major threat in H01CC?
For most core anti-GnRH therapies in H01CC, biosimilar threat is limited because the marketed agents are typically small molecules rather than biologics.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- EMA. European Medicines Agency: product information and public assessment documents for GnRH antagonists and related therapies. European Medicines Agency.
- FDA. Guidance for Industry: Paragraph IV Certifications and Related Issues. U.S. Food and Drug Administration.
- U.S. Code. 35 U.S.C. 156 (Patent Term Restoration) and 42 U.S.C. 262 (Biologics exclusivity framework where applicable).
More… ↓
